Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 39

Sort by

Sort Order Select

Journal Articles

The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma

Blood (2024) 144 (7): 771–783.

https://doi.org/10.1182/blood.2024024299

Published: 2024

Includes: Supplemental data

Journal Articles

Closing the Efficacy and Effectiveness Gap: Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) in Routine Clinical Practice Remain Comparable to the Outcomes Reported in the Phase 3 Tourmaline-MM1 Study

Roman Hajek, Prof, MD PhD, Jiri Minarik, MD PhD, Jan Straub, MD, Ludek Pour, MD, Alexandra Jungova, Jesus G. Berdeja, MD, Mario Boccadoro, Lucie Brožová, MSc, Andrew Spencer, MBBS, FRACP, FRCPA, DM, Frits van Rhee, MD PhD, Jorge Vela-Ojeda, MD PhD, Michael A. Thompson, MD PhD FASCO, Rafat Abonour, MD, Ajai Chari, MD, Gordon Cook, MB ChB, PhD FRCP(Glas), FRCPath, Caitlin L. Costello, MD, Faith E. Davies, MD, Vania T.M. Hungria, MD PhD, Hans C. Lee, MD, Xavier Leleu, MD PhD, Noemi Puig, MD PhD, Robert M. Rifkin, MD, Evangelos Terpos, MD PhD, Saad Z. Usmani, MD FACP, Katja C. Weisel, MD, Jeffrey A. Zonder, Magda Bařinová, MSc, Matyáš Kuhn, MSc, Jiri Silar, MSc, Lenka Capkova, Kenny Galvez, MD, Jin Lu, MDProf, Tomas Skacel, MD, Jennifer Elliott, Brittany Demers, BS, BA, Dawn Marie Stull, Pharm.D., BCOP, Kaili Ren, PhD, Vladimir Maisnar, MD PhD MBA

Blood (2019) 134 (Supplement_1): 1845.

https://doi.org/10.1182/blood-2019-126606

Published: 2019

Journal Articles

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant: Updated Analysis of Maia

Blood (2019) 134 (Supplement_1): 1875.

https://doi.org/10.1182/blood-2019-123426

Published: 2019

Journal Articles

Efficacy of Pomalidomide, Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma Post-Lenalidomide: Results from a Systematic Literature Review and Indirect Treatment Comparison

Katja C. Weisel, MD, Sujith Dhanasiri, Aline Gauthier, Amie Padhiar, Eva Casal, Paul G. Richardson, MD

Blood (2019) 134 (Supplement_1): 2201.

https://doi.org/10.1182/blood-2019-123639

Published: 2019

Journal Articles

Pomalidomide + Bortezomib + Low-Dose Dexamethasone after 1 Prior Line of Therapy in Patients with Lenalidomide-Pretreated Multiple Myeloma: Subanalysis of the Phase 3 Optimismm Trial By Patient Age and Prior Stem Cell Transplant

Blood (2019) 134 (Supplement_1): 3120.

https://doi.org/10.1182/blood-2019-124349

Published: 2019

Journal Articles

Characterization of Relapse and Second-Line Therapy in Lenalidomide-Refractory, Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma: A Subanalysis of the Phase 3 First Trial

Salmon Manier, Meletios A. Dimopoulos, MD, Cyrille Hulin, MD, Xavier Leleu, MD PhD, Michel Delforge, Katja C. Weisel, MD, Ruiyun Jiang, Shankar Srinivasan, PhD MBA, Bruno Costa, Suzanne Robinson, Thierry Facon, MD

Blood (2019) 134 (Supplement_1): 3122.

https://doi.org/10.1182/blood-2019-124557

Published: 2019

Journal Articles

Efficacy and Safety of Daratumumab, Bortezomib, and Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in First Relapse Patients (pts) with Multiple Myeloma (MM): Four-Year Update of Castor

Katja C. Weisel, MD, Pieter Sonneveld, Maria-Victoria Mateos, Vania T.M. Hungria, MD PhD, Andrew Spencer, MBBS, FRACP, FRCPA, DM, Jane Estell, FRACP, Wolney G Barreto, Paolo Corradini, Chang-Ki Min, MD PhD, Eva Medvedova, MD, Maria Krevvata, PhD, Sonali Trivedi, Xiang Qin, Huiling Pei, PhD, Jon Ukropec, PhD, Rachel Kobos, MD, Ming Qi, MD PhD, Ajay K Nooka, MDMPH

Blood (2019) 134 (Supplement_1): 3192.

https://doi.org/10.1182/blood-2019-123527

Published: 2019

Journal Articles

Real-World (RW) Multiple Myeloma (MM) Patients (Pts) Remain Under-Represented in Clinical Trials Based on Standard Laboratory Parameters and Baseline Characteristics: Analysis of over 3,000 Pts from the Insight MM Global, Prospective, Observational Study

Blood (2019) 134 (Supplement_1): 1887.

https://doi.org/10.1182/blood-2019-125749

Published: 2019

Journal Articles

A Predictive Score for Early Mortality during Induction Therapy in Newly Diagnosed Transplant-Eligible Multiple Myeloma - an Analysis from Five GMMG and HOVON Multicenter Phase III Trials

Blood (2017) 130 (Supplement 1): 2016.

https://doi.org/10.1182/blood.V130.Suppl_1.2016.2016

Published: 2017

Journal Articles

Response-Adapted Lenalidomide Maintenance in Newly Diagnosed, Transplant-Eligible Multiple Myeloma: Results from the Multicenter Phase III GMMG-MM5 Trial

Blood (2017) 130 (Supplement 1): 400.

https://doi.org/10.1182/blood.V130.Suppl_1.400.400

Published: 2017

Journal Articles

Circulating Tumor Cells As a Surrogate Marker for Bone Marrow Minimal Residual Disease and an Adverse Prognostic Factor for Patients with Multiple Myelom

Stefanie Huhn, PhD, Mathias Hänel, MD, Thomas Hielscher, PhD, Uta Bertsch, MD, Hans Jürgen Salwender, Norma Peter, MD, Hartmut Kirchner, Helga Bernhard, MD, Martin Vogel, Ralf Angermund, Martin Goerner, MD, Katja C. Weisel, Jan Duering, Igor W Blau, Niels Weinhold, PhD, Hartmut Goldschmidt, MD

Blood (2017) 130 (Supplement 1): 4359.

https://doi.org/10.1182/blood.V130.Suppl_1.4359.4359

Published: 2017

Journal Articles

Correlative Analyses of Cereblon ( CRBN ), cMYC , IRF4 , BLIMP1 , and XBP1 with Clinical Outcomes in Stratus (MM-010), a Phase 3b Study of Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Xiaozhong Qian, Meletios A. Dimopoulos, Michael Amatangelo, PhD, Chad Bjorklund, Katja C. Weisel, Enrique M. Ocio, MDPhD, Xin Yu, Teresa Peluso, Lars Sternas, Mohamed Zaki, Philippe Moreau, MDPhD, Anjan Thakurta, PhD

Blood (2017) 130 (Supplement 1): 3109.

https://doi.org/10.1182/blood.V130.Suppl_1.3109.3109

Published: 2017

Journal Articles

Daratumumab, Bortezomib, and Dexamethasone (DVd) Versus Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma (RRMM): Updated Efficacy and Safety Analysis of Castor

Andrew Spencer, MD, Vania T M Hungria, MD PhD, Maria-Victoria Mateos, MD, Ajay Nooka, MDMPH, Jane Estell, Wolney G Barreto, Paolo Corradini, MD, Chang-Ki Min, MD, Eva Medvedova, MD, Piruntha Thiyagarajah, William Deraedt, Christopher Chiu, Jordan Schecter, Katja C. Weisel

Blood (2017) 130 (Supplement 1): 3145.

https://doi.org/10.1182/blood.V130.Suppl_1.3145.3145

Published: 2017

Journal Articles

Direct Assessment of IgA and IgG Paraprotein By Hevylite Assay and Correlation to IMWG Response and Progression-Free Survival in Newly Diagnosed, Transplant-Eligible Multiple Myeloma Patients in the Prospective Phase III GMMG-MM5 Trial

Blood (2017) 130 (Supplement 1): 1784.

https://doi.org/10.1182/blood.V130.Suppl_1.1784.1784

Published: 2017

Journal Articles

The Prognostic and Predictive Value of IKZF1 and IKZF3 Expression in T-Cells in Patients with Multiple Myeloma

Mohamed H.S. Awwad, Katharina Kriegsmann, MD MBA, Julian Plaumann, Michael Benn, Jens Hillengass, MD, Marc-Steffen S Raab, Uta Bertsch, MD, Markus Munder, MD, Katja C. Weisel, Hans Jürgen Salwender, Mathias Hänel, MD, Roland Fenk, MD, Jan Dürig, MD, Carsten Müller-Tidow, Hartmut Goldschmidt, MD, Michael Hundemer

Blood (2017) 130 (Supplement 1): 1846.

https://doi.org/10.1182/blood.V130.Suppl_1.1846.1846

Published: 2017

Journal Articles

MM-013 Phase 2, Multicenter Study of Pomalidomide (POM) Plus Low-Dose Dexamethasone (LoDEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) and Renal Impairment (RI): Pharmacokinetics (PK) Analysis

Pieter Sonneveld, MDPhD, Katja C. Weisel, Yan Li, Elisabeth Kueenburg, Shona Collins, Antonia Di Micco, Barbara Rosettani, Pamela Bacon, Meletios A. Dimopoulos

Blood (2017) 130 (Supplement 1): 1847.

https://doi.org/10.1182/blood.V130.Suppl_1.1847.1847

Published: 2017

Journal Articles

Addition of Cyclophosphamide to Pomalidomide and Dexamethasone in Case of Suboptimal Response to Pomalidomide and Dexamethasone Alone in Relapsed and/or Refractory Multiple Myeloma: Results of the GMMG-Perspective Trial

Katja C. Weisel, Hans Jürgen Salwender, Christof Scheid, MD, Manola Zago, Britta Besemer, Mathias Hänel, MD, Jan Dürig, MD, Markus Munder, MD, Hans-Walter Lindemann, Anja Seckinger, Christina Kunz, Axel Benner, Dirk Hose, MD, Anna Jauch, Lothar Kanz, Hartmut Goldschmidt, MD

Blood (2017) 130 (Supplement 1): 1849.

https://doi.org/10.1182/blood.V130.Suppl_1.1849.1849

Published: 2017

Journal Articles

Overall Survival of Patients with Relapsed Multiple Myeloma Treated with Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone According to Prior Line of Therapy and Previous Exposure to Bortezomib: Secondary Analysis of the Phase 3 Endeavor Study

Katja C. Weisel, David Siegel, MD PhD, Jesus F. San Miguel, MD, Roman Hájek, MD, P. Joy Ho, MBBS, DPhil, FRACP, FRCPA, FFSc(RCPA), Gianluca Gaidano, MD PhD, Robert Z. Orlowski, MD PhD, Lifen Zhou, Amy S. Kimball, Philippe Moreau, MDPhD

Blood (2017) 130 (Supplement 1): 1850.

https://doi.org/10.1182/blood.V130.Suppl_1.1850.1850

Published: 2017

Journal Articles

Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma during Treatment with Ixazomib-Thalidomide-Dexamethasone Followed By Ixazomib Maintenance

Heinz Ludwig, MD, Wolfram Pönisch, MD, Alexander Egle, MD, Stefan Knop, MD, Martin Schreder, MD, Daniel Lechner, MD, Roman Hajek, Eberhard Gunsilius, Michael A. Fridrik, MD, Andreas Petzer, MD, Katja C. Weisel, Dietger Niederwieser, MD, Axel Hinke, PhD, Richard Greil, MD, Niklas Zojer, MD

Blood (2017) 130 (Supplement 1): 1857.

https://doi.org/10.1182/blood.V130.Suppl_1.1857.1857

Published: 2017

Journal Articles

Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma

Blood (2016) 128 (4): 497–503.

https://doi.org/10.1182/blood-2016-02-700872

Published: 2016

NARROW

The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma

Closing the Efficacy and Effectiveness Gap: Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) in Routine Clinical Practice Remain Comparable to the Outcomes Reported in the Phase 3 Tourmaline-MM1 Study

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant: Updated Analysis of Maia

Efficacy of Pomalidomide, Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma Post-Lenalidomide: Results from a Systematic Literature Review and Indirect Treatment Comparison

Pomalidomide + Bortezomib + Low-Dose Dexamethasone after 1 Prior Line of Therapy in Patients with Lenalidomide-Pretreated Multiple Myeloma: Subanalysis of the Phase 3 Optimismm Trial By Patient Age and Prior Stem Cell Transplant

Characterization of Relapse and Second-Line Therapy in Lenalidomide-Refractory, Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma: A Subanalysis of the Phase 3 First Trial

Efficacy and Safety of Daratumumab, Bortezomib, and Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in First Relapse Patients (pts) with Multiple Myeloma (MM): Four-Year Update of Castor

Real-World (RW) Multiple Myeloma (MM) Patients (Pts) Remain Under-Represented in Clinical Trials Based on Standard Laboratory Parameters and Baseline Characteristics: Analysis of over 3,000 Pts from the Insight MM Global, Prospective, Observational Study

A Predictive Score for Early Mortality during Induction Therapy in Newly Diagnosed Transplant-Eligible Multiple Myeloma - an Analysis from Five GMMG and HOVON Multicenter Phase III Trials

Response-Adapted Lenalidomide Maintenance in Newly Diagnosed, Transplant-Eligible Multiple Myeloma: Results from the Multicenter Phase III GMMG-MM5 Trial

Circulating Tumor Cells As a Surrogate Marker for Bone Marrow Minimal Residual Disease and an Adverse Prognostic Factor for Patients with Multiple Myelom

Correlative Analyses of Cereblon ( CRBN ), cMYC , IRF4 , BLIMP1 , and XBP1 with Clinical Outcomes in Stratus (MM-010), a Phase 3b Study of Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Daratumumab, Bortezomib, and Dexamethasone (DVd) Versus Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma (RRMM): Updated Efficacy and Safety Analysis of Castor

Direct Assessment of IgA and IgG Paraprotein By Hevylite Assay and Correlation to IMWG Response and Progression-Free Survival in Newly Diagnosed, Transplant-Eligible Multiple Myeloma Patients in the Prospective Phase III GMMG-MM5 Trial

The Prognostic and Predictive Value of IKZF1 and IKZF3 Expression in T-Cells in Patients with Multiple Myeloma

MM-013 Phase 2, Multicenter Study of Pomalidomide (POM) Plus Low-Dose Dexamethasone (LoDEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) and Renal Impairment (RI): Pharmacokinetics (PK) Analysis

Addition of Cyclophosphamide to Pomalidomide and Dexamethasone in Case of Suboptimal Response to Pomalidomide and Dexamethasone Alone in Relapsed and/or Refractory Multiple Myeloma: Results of the GMMG-Perspective Trial

Overall Survival of Patients with Relapsed Multiple Myeloma Treated with Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone According to Prior Line of Therapy and Previous Exposure to Bortezomib: Secondary Analysis of the Phase 3 Endeavor Study

Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma during Treatment with Ixazomib-Thalidomide-Dexamethasone Followed By Ixazomib Maintenance

Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only